Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
No matter what your view of Hardides progress this is NOT a bucket shop stock with bucket shop placings though the recent placing resembled one with a scandalous 21% discount to the SP. Disgusting IMHO. However, that said, investors in the placing are not, imo, going to be able to shift their shares even if they wanted to. The reason? This stock is extremely illiquid. They simply wouldn’t be able to offload on the market unless they could negotiate an off market bulk sale. And why would you when you have taken the shares at a going bust price?
No I don’t see overhang as an issue here. The issue is the fundamentals. Can they get the sales to drive the revenue back up? I don’t see a lot of scope for further downside here. It’s now a classic recovery play at this price.
Barnacle - that’s no less than TWO separate Innovation Awards in India in FOUR days for Bleepa. Impressive indeed. Now we can confidently expect this to be translated into incoming business as both these two occasions were great sales and marketing breakthroughs putting us (as Tom would say) ‘under the noses’ of all the right connected people within India’s healthcare industry.
Anish Patel (CFO) has stated ‘Very confident of business in the short term’.
Other thing I’d like to mention is the £300k award for the new Pilots is for just THREE months work to 31.3.2024. This would translate to £1.2m if awarded for 12 months equivalent. And that figure is considerably more eye catching when you compare to a paltry current MC @ £9m.
Coffee - not a bad way to look at the opportunity here. India is an absolutely mind blowingly humongous opportunity. It would gulf the NHS many times over. In terms of India I think we have a fantastic foot in the door through the recruitment of Rohit Singh. This guy was with the UK India Business Council for TEN years before joining Feedback six month’s ago. He must have an impressive range of connections with Indian business. That is for sure. So this guy has a network of contacts and a creditable profile known and respected within the Indian business community. I don’t think we, as a very small company, could possibly have a better chance of winning business in India than through this guy. Hell, Bleepa has already won an innovative award in India and he hasn’t even been in the post for six months.
The CFO has stated he is VERY confident of winning new business in the short term. Tom has stated that Rohit has already built a sizeable pipeline of opportunities.
coffee - maybe, just maybe it will be India that opens the floodgates, particularly with the VERY timely introduction of their own Data Protection Act. Perfect. Surely we won’t snatch defeat from the jaws of impending victory.
John Peter Lobbenberg - an 84 year old former Chartered Accountant (not normally the kind of profile that take huge risks!)
Also previously ran a Portfolio Management group.
This company is currently priced to go bust. I’m roughly 50% down with an average of 9.75p
But tempted to average down because they will either get taken out or recover, or both.
The guy clearly has his head screwed on then. Speaking of professional investors if you check out FDBK posts on LinkedIn you will often find a number of professional investors and well connected people in the healthcare space liking their posts. I read this as a good indicator and an endorsement of my own interest.
So did anyone else come out of yesterday’s InvestorMeet meeting with renewed positivity?
A number of potential short term catalysts now for SP growth. As I have stated on here before a number of times we are NAILED ON now to get the QVC contract which is worth £1.6m over 2 years and this will be a long term recurring revenue arrangement. QVC is the flagship CDC pilot which forms the blueprint for follower Trusts to adopt. The two more recently awarded CDC pilots are due to finish the end of next month (31 March) so we can expect to hear news there on the next steps (contract awards or further pilot extensions). Keep in mind the two recent pilots have been awarded at a NATIONAL level by NHS England os this is now being looked at closely at a NATIONAL level. FDBK yesterday confirmed they have been discussing possible deals with up to 20 CDC’s. We can expect this figure to rise as interest grows.
Then we have the entry into private healthcare which loooks more and more interesting as one sees the possibilities, including winning outsourced NHS work.
And then India which looks like becoming an additional revenue stream. The CFO yesterday confirmed that they are expecting contract/pilot news developments in the short term stating they are very confident of this with Rohit Singh building a growing pipeline of prospects including large hospital groups. India are currently implementing a data protection law which will preclude the use of WhatsApp.
So very interesting times ahead after a long wait for things to finally come together.
Coffeecups - I’m a little surprised by the lack of any negative reaction to this morning’s announcement. Perhaps it’s because the lack of any concrete positive news was already baked into the SP. As IB has said SP pretty much at atl.
As regards India I think Tom needs to be clearer about where exactly their target markets are. They have one guy out there and who is he talking to? The potential is huge but you need to know where to target most effectively your limited resources. At least this guy has pedigree and very good knowledge and links to the Indian market. So that is encouraging.
I think, as regards to the NHS and specifically CDC’s they WILL crack it. It’s just taking longer than optimistic people like me hoped. There isn’t any longer any question as to the benefits of Bleepa AND they have a large moat and a USP (only certified medical imaging device in UK)
It’s all about the money being made available to build up the digital side to garner those benefits. Have investors got the patience?
I think we’re very close. He has taken an understandably more cautious tone than previous - with enough encouragement on the flip side. I would say funding is good for another 12-18 months so no probs there for the time being.
For me QVH is KEY to unlocking the potential here.
Hi Barnacle - QVH tender news must be very close. Only one of two possible outcomes:
1. FDBK Win
2. Another issue with tender like last year
QVH Win is imperative and significant if FDBK win it.
Dusty you don’t actually have anything useful to contribute to the debate other than to childishly berate another poster with the preposterous suggestion that he is in someway responsible for the share price drop. This is an indication of highly immature investing awareness. Focus on the fundamentals. Focus on the facts.
The market is merely signposting the placing which will drop imo within the next four weeks.
And yes, because the SP has dropped so much it will be significantly dilutive.
RNS issued this morning but not shown on LSE:
https://www.londonstockexchange.com/news-article/COBR/ree-exploration-strategy-to-include-uranium/16327250
Al180 - the barriers to entry for competitors is very high. The Moat is very wide. There are no other comparable competitors in view of the impending ban on HCP later this year. Hardide have a pretty clear run at this. However, they will need to scale at some point and THAT for me is the crux. They don’t have the capacity to scale to meet the potential future demand and, therefore, there is only one solution. Get bought out by someone who can help them realise the potential. It simply has to happen as we can’t have a continuation of the snails pace progress we’ve seen up to now. And that’s why I think we are seeing very different noises from the company now leading up to Phil Kirkhams departure.
Pony - I agree but the longer you leave it and the higher the price moves your profit dwindles accordingly. Much like if you bought a share low, make a big profit and then the profit takers move in and you watch your profit disappear. But as you say, much depends on when they took out their position.